| 000 | 01575 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513143322.0 | ||
| 264 | 0 | _c19980707 | |
| 008 | 199807s 0 0 eng d | ||
| 022 | _a0091-2700 | ||
| 024 | 7 |
_a10.1002/j.1552-4604.1998.tb04448.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKoneru, B | |
| 245 | 0 | 0 |
_aEffect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _cMay 1998 |
||
| 300 |
_a429-32 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aCardiotonic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aFamotidine _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHistamine H2 Antagonists _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrogen-Ion Concentration _xdrug effects |
| 650 | 0 | 4 |
_aIntestinal Absorption _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aPyrazines |
| 650 | 0 | 4 |
_aQuinolines _xadministration & dosage |
| 700 | 1 | _aCowart, D T | |
| 700 | 1 | _aNoorisa, M | |
| 700 | 1 | _aKisicki, J | |
| 700 | 1 | _aBramer, S L | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 38 _gno. 5 _gp. 429-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/j.1552-4604.1998.tb04448.x _zAvailable from publisher's website |
| 999 |
_c9569654 _d9569654 |
||